Clinical Trials Directory

Trials / Completed

CompletedNCT06960239

Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children

Evaluation of the Efficacy and Safety of an Irreversible Electroporation (IRE) System for The Treatment of Upper Airway Obstruction Due to Adenotonsillar Hypertrophy in Children

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
31 (actual)
Sponsor
ENTire Medical Ltd. · Industry
Sex
All
Age
3 Years – 18 Years
Healthy volunteers
Accepted

Summary

This is a multi-center, prospective, open-label, traditional feasibility study with a before-after study design. The study is designed to evaluate the safety and efficacy of an Irreversible Electroporation (IRE) System for the treatment of upper airway obstruction due to adenotonsillar hypertrophy in Children.

Detailed description

The purpose of the IRE System is to address the clinical need for reducing the volume of hypertrophic tonsil(s) and adenoid while minimizing side effects and complications. Procedure time will also be reduced. The IRE System is designed to be more comfortable for patients, as it employs a noninvasive procedure using a high voltage pulsed electric field to create irreversible nanopores in the cell membrane, leading to cell death and the reduction of the tonsils and adenoid volume. On basis of these finding and in view of the known safety profile and efficacy of current adeno-tonsillar reduction technologies, the purpose of the current study is to prospectively determine the efficacy and safety of the IRE System in adeno-tonsillar reduction.

Conditions

Interventions

TypeNameDescription
DEVICEIRE SystemIrreversible Electroporation (IRE) System for the Treatment of Upper Airway Obstruction due to Adenotonsillar Hypertrophy in Children

Timeline

Start date
2024-11-14
Primary completion
2025-10-22
Completion
2025-10-22
First posted
2025-05-07
Last updated
2026-03-18

Locations

2 sites across 2 countries: Romania, Uzbekistan

Source: ClinicalTrials.gov record NCT06960239. Inclusion in this directory is not an endorsement.